nodes	percent_of_prediction	percent_of_DWPC	metapath
Bortezomib—SLC31A1—Cisplatin—peripheral nervous system neoplasm	0.259	0.467	CbGbCtD
Bortezomib—CYP1A1—Tretinoin—peripheral nervous system neoplasm	0.0529	0.0954	CbGbCtD
Bortezomib—CYP1A1—Dacarbazine—peripheral nervous system neoplasm	0.0455	0.082	CbGbCtD
Bortezomib—CYP2C8—Tretinoin—peripheral nervous system neoplasm	0.0305	0.055	CbGbCtD
Bortezomib—CYP1A2—Alitretinoin—peripheral nervous system neoplasm	0.0254	0.0458	CbGbCtD
Bortezomib—PTGS1—Etoposide—peripheral nervous system neoplasm	0.0223	0.0401	CbGbCtD
Bortezomib—CYP2C9—Tretinoin—peripheral nervous system neoplasm	0.0213	0.0384	CbGbCtD
Bortezomib—CYP1A2—Dacarbazine—peripheral nervous system neoplasm	0.0203	0.0366	CbGbCtD
Bortezomib—CYP3A4—Topotecan—peripheral nervous system neoplasm	0.0133	0.024	CbGbCtD
Bortezomib—CYP2C8—Etoposide—peripheral nervous system neoplasm	0.0128	0.0232	CbGbCtD
Bortezomib—CYP3A4—Tretinoin—peripheral nervous system neoplasm	0.0124	0.0223	CbGbCtD
Bortezomib—CYP1A2—Etoposide—peripheral nervous system neoplasm	0.00994	0.0179	CbGbCtD
Bortezomib—CYP2C9—Cisplatin—peripheral nervous system neoplasm	0.00912	0.0164	CbGbCtD
Bortezomib—CYP3A4—Vincristine—peripheral nervous system neoplasm	0.00568	0.0103	CbGbCtD
Bortezomib—CYP2D6—Doxorubicin—peripheral nervous system neoplasm	0.00559	0.0101	CbGbCtD
Bortezomib—CYP3A4—Etoposide—peripheral nervous system neoplasm	0.00521	0.00939	CbGbCtD
Bortezomib—CYP3A4—Doxorubicin—peripheral nervous system neoplasm	0.00355	0.00641	CbGbCtD
Bortezomib—PSMD1—trigeminal ganglion—peripheral nervous system neoplasm	0.00202	0.0722	CbGeAlD
Bortezomib—PSMD1—parotid gland—peripheral nervous system neoplasm	0.00191	0.0681	CbGeAlD
Bortezomib—PSMD2—trigeminal ganglion—peripheral nervous system neoplasm	0.00179	0.064	CbGeAlD
Bortezomib—PSMB8—trigeminal ganglion—peripheral nervous system neoplasm	0.00178	0.0636	CbGeAlD
Bortezomib—PSMD2—parotid gland—peripheral nervous system neoplasm	0.00169	0.0603	CbGeAlD
Bortezomib—PSMB8—parotid gland—peripheral nervous system neoplasm	0.00168	0.06	CbGeAlD
Bortezomib—PSMB8—Vinorelbine—Vincristine—peripheral nervous system neoplasm	0.00166	0.5	CbGdCrCtD
Bortezomib—PSMB8—Podofilox—Etoposide—peripheral nervous system neoplasm	0.00166	0.5	CbGdCrCtD
Bortezomib—PSMB5—trigeminal ganglion—peripheral nervous system neoplasm	0.00157	0.0562	CbGeAlD
Bortezomib—PSMB5—parotid gland—peripheral nervous system neoplasm	0.00148	0.053	CbGeAlD
Bortezomib—PSMB1—trigeminal ganglion—peripheral nervous system neoplasm	0.00137	0.0491	CbGeAlD
Bortezomib—PSMB2—trigeminal ganglion—peripheral nervous system neoplasm	0.00134	0.0479	CbGeAlD
Bortezomib—PSMB1—parotid gland—peripheral nervous system neoplasm	0.00129	0.0463	CbGeAlD
Bortezomib—PSMB2—parotid gland—peripheral nervous system neoplasm	0.00126	0.0452	CbGeAlD
Bortezomib—SLC31A1—trigeminal ganglion—peripheral nervous system neoplasm	0.00116	0.0415	CbGeAlD
Bortezomib—SLC31A1—parotid gland—peripheral nervous system neoplasm	0.00109	0.0391	CbGeAlD
Bortezomib—PSMA1—cerebellum—peripheral nervous system neoplasm	0.00105	0.0375	CbGeAlD
Bortezomib—PSMD1—cerebellum—peripheral nervous system neoplasm	0.000881	0.0315	CbGeAlD
Bortezomib—PSMD2—cerebellum—peripheral nervous system neoplasm	0.000781	0.0279	CbGeAlD
Bortezomib—PTGS1—ganglion—peripheral nervous system neoplasm	0.000705	0.0252	CbGeAlD
Bortezomib—PSMB5—cerebellum—peripheral nervous system neoplasm	0.000685	0.0245	CbGeAlD
Bortezomib—PSMB1—cerebellum—peripheral nervous system neoplasm	0.000599	0.0214	CbGeAlD
Bortezomib—PSMB2—cerebellum—peripheral nervous system neoplasm	0.000584	0.0209	CbGeAlD
Bortezomib—SLC31A1—cerebellum—peripheral nervous system neoplasm	0.000506	0.0181	CbGeAlD
Bortezomib—CYP1A1—parotid gland—peripheral nervous system neoplasm	0.000372	0.0133	CbGeAlD
Bortezomib—CYP2D6—brainstem—peripheral nervous system neoplasm	0.000252	0.009	CbGeAlD
Bortezomib—CYP2D6—cerebellum—peripheral nervous system neoplasm	0.000124	0.00444	CbGeAlD
Bortezomib—Dyspnoea—Etoposide—peripheral nervous system neoplasm	4.51e-05	0.000146	CcSEcCtD
Bortezomib—Hyperglycaemia—Epirubicin—peripheral nervous system neoplasm	4.5e-05	0.000146	CcSEcCtD
Bortezomib—Angina pectoris—Doxorubicin—peripheral nervous system neoplasm	4.5e-05	0.000146	CcSEcCtD
Bortezomib—Asthenia—Vincristine—peripheral nervous system neoplasm	4.48e-05	0.000145	CcSEcCtD
Bortezomib—Pneumonia—Epirubicin—peripheral nervous system neoplasm	4.47e-05	0.000145	CcSEcCtD
Bortezomib—Infestation NOS—Epirubicin—peripheral nervous system neoplasm	4.45e-05	0.000144	CcSEcCtD
Bortezomib—Infestation—Epirubicin—peripheral nervous system neoplasm	4.45e-05	0.000144	CcSEcCtD
Bortezomib—Vomiting—Dactinomycin—peripheral nervous system neoplasm	4.45e-05	0.000144	CcSEcCtD
Bortezomib—Bronchitis—Doxorubicin—peripheral nervous system neoplasm	4.44e-05	0.000144	CcSEcCtD
Bortezomib—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	4.44e-05	0.000144	CcSEcCtD
Bortezomib—Stevens-Johnson syndrome—Epirubicin—peripheral nervous system neoplasm	4.41e-05	0.000143	CcSEcCtD
Bortezomib—Rash—Dactinomycin—peripheral nervous system neoplasm	4.41e-05	0.000143	CcSEcCtD
Bortezomib—Decreased appetite—Etoposide—peripheral nervous system neoplasm	4.4e-05	0.000143	CcSEcCtD
Bortezomib—Pancytopenia—Doxorubicin—peripheral nervous system neoplasm	4.38e-05	0.000142	CcSEcCtD
Bortezomib—Renal failure—Epirubicin—peripheral nervous system neoplasm	4.37e-05	0.000142	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	4.37e-05	0.000142	CcSEcCtD
Bortezomib—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	4.37e-05	0.000142	CcSEcCtD
Bortezomib—Fatigue—Etoposide—peripheral nervous system neoplasm	4.36e-05	0.000142	CcSEcCtD
Bortezomib—Neuropathy peripheral—Epirubicin—peripheral nervous system neoplasm	4.36e-05	0.000141	CcSEcCtD
Bortezomib—Stomatitis—Epirubicin—peripheral nervous system neoplasm	4.34e-05	0.000141	CcSEcCtD
Bortezomib—Pain—Etoposide—peripheral nervous system neoplasm	4.33e-05	0.00014	CcSEcCtD
Bortezomib—Constipation—Etoposide—peripheral nervous system neoplasm	4.33e-05	0.00014	CcSEcCtD
Bortezomib—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	4.32e-05	0.00014	CcSEcCtD
Bortezomib—Conjunctivitis—Epirubicin—peripheral nervous system neoplasm	4.32e-05	0.00014	CcSEcCtD
Bortezomib—Neutropenia—Doxorubicin—peripheral nervous system neoplasm	4.32e-05	0.00014	CcSEcCtD
Bortezomib—Upper respiratory tract infection—Doxorubicin—peripheral nervous system neoplasm	4.29e-05	0.000139	CcSEcCtD
Bortezomib—Dizziness—Alitretinoin—peripheral nervous system neoplasm	4.29e-05	0.000139	CcSEcCtD
Bortezomib—Diarrhoea—Vincristine—peripheral nervous system neoplasm	4.27e-05	0.000139	CcSEcCtD
Bortezomib—Pollakiuria—Doxorubicin—peripheral nervous system neoplasm	4.26e-05	0.000138	CcSEcCtD
Bortezomib—Haematuria—Epirubicin—peripheral nervous system neoplasm	4.24e-05	0.000138	CcSEcCtD
Bortezomib—Photosensitivity reaction—Doxorubicin—peripheral nervous system neoplasm	4.21e-05	0.000137	CcSEcCtD
Bortezomib—Hepatobiliary disease—Epirubicin—peripheral nervous system neoplasm	4.21e-05	0.000136	CcSEcCtD
Bortezomib—Weight increased—Doxorubicin—peripheral nervous system neoplasm	4.2e-05	0.000136	CcSEcCtD
Bortezomib—Epistaxis—Epirubicin—peripheral nervous system neoplasm	4.2e-05	0.000136	CcSEcCtD
Bortezomib—Weight decreased—Doxorubicin—peripheral nervous system neoplasm	4.18e-05	0.000136	CcSEcCtD
Bortezomib—Sinusitis—Epirubicin—peripheral nervous system neoplasm	4.17e-05	0.000135	CcSEcCtD
Bortezomib—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	4.17e-05	0.000135	CcSEcCtD
Bortezomib—Hyperglycaemia—Doxorubicin—peripheral nervous system neoplasm	4.16e-05	0.000135	CcSEcCtD
Bortezomib—Nausea—Dactinomycin—peripheral nervous system neoplasm	4.15e-05	0.000135	CcSEcCtD
Bortezomib—Pneumonia—Doxorubicin—peripheral nervous system neoplasm	4.14e-05	0.000134	CcSEcCtD
Bortezomib—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	4.14e-05	0.000134	CcSEcCtD
Bortezomib—Dizziness—Vincristine—peripheral nervous system neoplasm	4.13e-05	0.000134	CcSEcCtD
Bortezomib—Vomiting—Alitretinoin—peripheral nervous system neoplasm	4.12e-05	0.000134	CcSEcCtD
Bortezomib—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	4.12e-05	0.000134	CcSEcCtD
Bortezomib—Infestation—Doxorubicin—peripheral nervous system neoplasm	4.12e-05	0.000134	CcSEcCtD
Bortezomib—Rash—Alitretinoin—peripheral nervous system neoplasm	4.09e-05	0.000133	CcSEcCtD
Bortezomib—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	4.08e-05	0.000133	CcSEcCtD
Bortezomib—Stevens-Johnson syndrome—Doxorubicin—peripheral nervous system neoplasm	4.08e-05	0.000132	CcSEcCtD
Bortezomib—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	4.07e-05	0.000132	CcSEcCtD
Bortezomib—Bradycardia—Epirubicin—peripheral nervous system neoplasm	4.06e-05	0.000132	CcSEcCtD
Bortezomib—Headache—Alitretinoin—peripheral nervous system neoplasm	4.06e-05	0.000132	CcSEcCtD
Bortezomib—Renal failure—Doxorubicin—peripheral nervous system neoplasm	4.05e-05	0.000131	CcSEcCtD
Bortezomib—Neuropathy peripheral—Doxorubicin—peripheral nervous system neoplasm	4.03e-05	0.000131	CcSEcCtD
Bortezomib—Urticaria—Etoposide—peripheral nervous system neoplasm	4.02e-05	0.00013	CcSEcCtD
Bortezomib—Haemoglobin—Epirubicin—peripheral nervous system neoplasm	4.01e-05	0.00013	CcSEcCtD
Bortezomib—Stomatitis—Doxorubicin—peripheral nervous system neoplasm	4.01e-05	0.00013	CcSEcCtD
Bortezomib—Abdominal pain—Etoposide—peripheral nervous system neoplasm	4e-05	0.00013	CcSEcCtD
Bortezomib—Body temperature increased—Etoposide—peripheral nervous system neoplasm	4e-05	0.00013	CcSEcCtD
Bortezomib—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	4e-05	0.00013	CcSEcCtD
Bortezomib—Conjunctivitis—Doxorubicin—peripheral nervous system neoplasm	4e-05	0.00013	CcSEcCtD
Bortezomib—Haemorrhage—Epirubicin—peripheral nervous system neoplasm	3.99e-05	0.00013	CcSEcCtD
Bortezomib—Hepatitis—Epirubicin—peripheral nervous system neoplasm	3.99e-05	0.00013	CcSEcCtD
Bortezomib—Hypoaesthesia—Epirubicin—peripheral nervous system neoplasm	3.97e-05	0.000129	CcSEcCtD
Bortezomib—Vomiting—Vincristine—peripheral nervous system neoplasm	3.97e-05	0.000129	CcSEcCtD
Bortezomib—Asthenia—Cisplatin—peripheral nervous system neoplasm	3.96e-05	0.000129	CcSEcCtD
Bortezomib—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	3.94e-05	0.000128	CcSEcCtD
Bortezomib—Rash—Vincristine—peripheral nervous system neoplasm	3.94e-05	0.000128	CcSEcCtD
Bortezomib—Dermatitis—Vincristine—peripheral nervous system neoplasm	3.94e-05	0.000128	CcSEcCtD
Bortezomib—Oedema peripheral—Epirubicin—peripheral nervous system neoplasm	3.93e-05	0.000128	CcSEcCtD
Bortezomib—Haematuria—Doxorubicin—peripheral nervous system neoplasm	3.92e-05	0.000127	CcSEcCtD
Bortezomib—Connective tissue disorder—Epirubicin—peripheral nervous system neoplasm	3.92e-05	0.000127	CcSEcCtD
Bortezomib—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	3.91e-05	0.000127	CcSEcCtD
Bortezomib—Headache—Vincristine—peripheral nervous system neoplasm	3.91e-05	0.000127	CcSEcCtD
Bortezomib—Hepatobiliary disease—Doxorubicin—peripheral nervous system neoplasm	3.89e-05	0.000126	CcSEcCtD
Bortezomib—Epistaxis—Doxorubicin—peripheral nervous system neoplasm	3.88e-05	0.000126	CcSEcCtD
Bortezomib—Sinusitis—Doxorubicin—peripheral nervous system neoplasm	3.86e-05	0.000125	CcSEcCtD
Bortezomib—Nausea—Alitretinoin—peripheral nervous system neoplasm	3.85e-05	0.000125	CcSEcCtD
Bortezomib—Visual impairment—Epirubicin—peripheral nervous system neoplasm	3.85e-05	0.000125	CcSEcCtD
Bortezomib—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	3.78e-05	0.000123	CcSEcCtD
Bortezomib—Erythema multiforme—Epirubicin—peripheral nervous system neoplasm	3.78e-05	0.000123	CcSEcCtD
Bortezomib—Bradycardia—Doxorubicin—peripheral nervous system neoplasm	3.76e-05	0.000122	CcSEcCtD
Bortezomib—Eye disorder—Epirubicin—peripheral nervous system neoplasm	3.73e-05	0.000121	CcSEcCtD
Bortezomib—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	3.73e-05	0.000121	CcSEcCtD
Bortezomib—Tinnitus—Epirubicin—peripheral nervous system neoplasm	3.72e-05	0.000121	CcSEcCtD
Bortezomib—Haemoglobin—Doxorubicin—peripheral nervous system neoplasm	3.71e-05	0.00012	CcSEcCtD
Bortezomib—Nausea—Vincristine—peripheral nervous system neoplasm	3.71e-05	0.00012	CcSEcCtD
Bortezomib—Flushing—Epirubicin—peripheral nervous system neoplasm	3.71e-05	0.00012	CcSEcCtD
Bortezomib—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	3.71e-05	0.00012	CcSEcCtD
Bortezomib—Hepatitis—Doxorubicin—peripheral nervous system neoplasm	3.69e-05	0.00012	CcSEcCtD
Bortezomib—Haemorrhage—Doxorubicin—peripheral nervous system neoplasm	3.69e-05	0.00012	CcSEcCtD
Bortezomib—Hypoaesthesia—Doxorubicin—peripheral nervous system neoplasm	3.68e-05	0.000119	CcSEcCtD
Bortezomib—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	3.65e-05	0.000118	CcSEcCtD
Bortezomib—Oedema peripheral—Doxorubicin—peripheral nervous system neoplasm	3.64e-05	0.000118	CcSEcCtD
Bortezomib—Asthenia—Etoposide—peripheral nervous system neoplasm	3.63e-05	0.000118	CcSEcCtD
Bortezomib—Connective tissue disorder—Doxorubicin—peripheral nervous system neoplasm	3.63e-05	0.000118	CcSEcCtD
Bortezomib—Angiopathy—Epirubicin—peripheral nervous system neoplasm	3.62e-05	0.000118	CcSEcCtD
Bortezomib—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	3.62e-05	0.000118	CcSEcCtD
Bortezomib—Immune system disorder—Epirubicin—peripheral nervous system neoplasm	3.61e-05	0.000117	CcSEcCtD
Bortezomib—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	3.6e-05	0.000117	CcSEcCtD
Bortezomib—Chills—Epirubicin—peripheral nervous system neoplasm	3.58e-05	0.000116	CcSEcCtD
Bortezomib—Pruritus—Etoposide—peripheral nervous system neoplasm	3.58e-05	0.000116	CcSEcCtD
Bortezomib—Arrhythmia—Epirubicin—peripheral nervous system neoplasm	3.57e-05	0.000116	CcSEcCtD
Bortezomib—Visual impairment—Doxorubicin—peripheral nervous system neoplasm	3.56e-05	0.000116	CcSEcCtD
Bortezomib—Vomiting—Cisplatin—peripheral nervous system neoplasm	3.51e-05	0.000114	CcSEcCtD
Bortezomib—Mental disorder—Epirubicin—peripheral nervous system neoplasm	3.5e-05	0.000114	CcSEcCtD
Bortezomib—Erythema multiforme—Doxorubicin—peripheral nervous system neoplasm	3.49e-05	0.000113	CcSEcCtD
Bortezomib—Rash—Cisplatin—peripheral nervous system neoplasm	3.48e-05	0.000113	CcSEcCtD
Bortezomib—Dermatitis—Cisplatin—peripheral nervous system neoplasm	3.48e-05	0.000113	CcSEcCtD
Bortezomib—Malnutrition—Epirubicin—peripheral nervous system neoplasm	3.48e-05	0.000113	CcSEcCtD
Bortezomib—Erythema—Epirubicin—peripheral nervous system neoplasm	3.48e-05	0.000113	CcSEcCtD
Bortezomib—Diarrhoea—Etoposide—peripheral nervous system neoplasm	3.46e-05	0.000112	CcSEcCtD
Bortezomib—Eye disorder—Doxorubicin—peripheral nervous system neoplasm	3.45e-05	0.000112	CcSEcCtD
Bortezomib—Tinnitus—Doxorubicin—peripheral nervous system neoplasm	3.44e-05	0.000112	CcSEcCtD
Bortezomib—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	3.43e-05	0.000111	CcSEcCtD
Bortezomib—Flushing—Doxorubicin—peripheral nervous system neoplasm	3.43e-05	0.000111	CcSEcCtD
Bortezomib—Flatulence—Epirubicin—peripheral nervous system neoplasm	3.42e-05	0.000111	CcSEcCtD
Bortezomib—Dysgeusia—Epirubicin—peripheral nervous system neoplasm	3.4e-05	0.00011	CcSEcCtD
Bortezomib—Back pain—Epirubicin—peripheral nervous system neoplasm	3.36e-05	0.000109	CcSEcCtD
Bortezomib—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	3.35e-05	0.000109	CcSEcCtD
Bortezomib—Dizziness—Etoposide—peripheral nervous system neoplasm	3.35e-05	0.000109	CcSEcCtD
Bortezomib—Muscle spasms—Epirubicin—peripheral nervous system neoplasm	3.34e-05	0.000108	CcSEcCtD
Bortezomib—Immune system disorder—Doxorubicin—peripheral nervous system neoplasm	3.34e-05	0.000108	CcSEcCtD
Bortezomib—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	3.33e-05	0.000108	CcSEcCtD
Bortezomib—Chills—Doxorubicin—peripheral nervous system neoplasm	3.31e-05	0.000108	CcSEcCtD
Bortezomib—Arrhythmia—Doxorubicin—peripheral nervous system neoplasm	3.3e-05	0.000107	CcSEcCtD
Bortezomib—Nausea—Cisplatin—peripheral nervous system neoplasm	3.28e-05	0.000106	CcSEcCtD
Bortezomib—Vision blurred—Epirubicin—peripheral nervous system neoplasm	3.28e-05	0.000106	CcSEcCtD
Bortezomib—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	3.24e-05	0.000105	CcSEcCtD
Bortezomib—Ill-defined disorder—Epirubicin—peripheral nervous system neoplasm	3.22e-05	0.000105	CcSEcCtD
Bortezomib—Vomiting—Etoposide—peripheral nervous system neoplasm	3.22e-05	0.000104	CcSEcCtD
Bortezomib—Erythema—Doxorubicin—peripheral nervous system neoplasm	3.22e-05	0.000104	CcSEcCtD
Bortezomib—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	3.22e-05	0.000104	CcSEcCtD
Bortezomib—Anaemia—Epirubicin—peripheral nervous system neoplasm	3.21e-05	0.000104	CcSEcCtD
Bortezomib—Agitation—Epirubicin—peripheral nervous system neoplasm	3.19e-05	0.000104	CcSEcCtD
Bortezomib—Rash—Etoposide—peripheral nervous system neoplasm	3.19e-05	0.000104	CcSEcCtD
Bortezomib—Dermatitis—Etoposide—peripheral nervous system neoplasm	3.19e-05	0.000103	CcSEcCtD
Bortezomib—Headache—Etoposide—peripheral nervous system neoplasm	3.17e-05	0.000103	CcSEcCtD
Bortezomib—Flatulence—Doxorubicin—peripheral nervous system neoplasm	3.17e-05	0.000103	CcSEcCtD
Bortezomib—Dysgeusia—Doxorubicin—peripheral nervous system neoplasm	3.15e-05	0.000102	CcSEcCtD
Bortezomib—Malaise—Epirubicin—peripheral nervous system neoplasm	3.13e-05	0.000102	CcSEcCtD
Bortezomib—Vertigo—Epirubicin—peripheral nervous system neoplasm	3.12e-05	0.000101	CcSEcCtD
Bortezomib—Syncope—Epirubicin—peripheral nervous system neoplasm	3.12e-05	0.000101	CcSEcCtD
Bortezomib—Leukopenia—Epirubicin—peripheral nervous system neoplasm	3.11e-05	0.000101	CcSEcCtD
Bortezomib—Back pain—Doxorubicin—peripheral nervous system neoplasm	3.11e-05	0.000101	CcSEcCtD
Bortezomib—Muscle spasms—Doxorubicin—peripheral nervous system neoplasm	3.09e-05	0.0001	CcSEcCtD
Bortezomib—Palpitations—Epirubicin—peripheral nervous system neoplasm	3.07e-05	9.97e-05	CcSEcCtD
Bortezomib—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	3.05e-05	9.91e-05	CcSEcCtD
Bortezomib—Cough—Epirubicin—peripheral nervous system neoplasm	3.03e-05	9.84e-05	CcSEcCtD
Bortezomib—Vision blurred—Doxorubicin—peripheral nervous system neoplasm	3.03e-05	9.84e-05	CcSEcCtD
Bortezomib—Convulsion—Epirubicin—peripheral nervous system neoplasm	3.01e-05	9.77e-05	CcSEcCtD
Bortezomib—Nausea—Etoposide—peripheral nervous system neoplasm	3.01e-05	9.75e-05	CcSEcCtD
Bortezomib—Hypertension—Epirubicin—peripheral nervous system neoplasm	3e-05	9.74e-05	CcSEcCtD
Bortezomib—Ill-defined disorder—Doxorubicin—peripheral nervous system neoplasm	2.98e-05	9.68e-05	CcSEcCtD
Bortezomib—Anaemia—Doxorubicin—peripheral nervous system neoplasm	2.97e-05	9.65e-05	CcSEcCtD
Bortezomib—Arthralgia—Epirubicin—peripheral nervous system neoplasm	2.96e-05	9.6e-05	CcSEcCtD
Bortezomib—Chest pain—Epirubicin—peripheral nervous system neoplasm	2.96e-05	9.6e-05	CcSEcCtD
Bortezomib—Myalgia—Epirubicin—peripheral nervous system neoplasm	2.96e-05	9.6e-05	CcSEcCtD
Bortezomib—Agitation—Doxorubicin—peripheral nervous system neoplasm	2.96e-05	9.59e-05	CcSEcCtD
Bortezomib—Anxiety—Epirubicin—peripheral nervous system neoplasm	2.95e-05	9.57e-05	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	2.94e-05	9.54e-05	CcSEcCtD
Bortezomib—Discomfort—Epirubicin—peripheral nervous system neoplasm	2.92e-05	9.49e-05	CcSEcCtD
Bortezomib—Malaise—Doxorubicin—peripheral nervous system neoplasm	2.9e-05	9.41e-05	CcSEcCtD
Bortezomib—Vertigo—Doxorubicin—peripheral nervous system neoplasm	2.89e-05	9.38e-05	CcSEcCtD
Bortezomib—Syncope—Doxorubicin—peripheral nervous system neoplasm	2.88e-05	9.36e-05	CcSEcCtD
Bortezomib—Leukopenia—Doxorubicin—peripheral nervous system neoplasm	2.88e-05	9.34e-05	CcSEcCtD
Bortezomib—Confusional state—Epirubicin—peripheral nervous system neoplasm	2.86e-05	9.28e-05	CcSEcCtD
Bortezomib—Palpitations—Doxorubicin—peripheral nervous system neoplasm	2.84e-05	9.22e-05	CcSEcCtD
Bortezomib—Anaphylactic shock—Epirubicin—peripheral nervous system neoplasm	2.84e-05	9.2e-05	CcSEcCtD
Bortezomib—Oedema—Epirubicin—peripheral nervous system neoplasm	2.84e-05	9.2e-05	CcSEcCtD
Bortezomib—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	2.83e-05	9.17e-05	CcSEcCtD
Bortezomib—Infection—Epirubicin—peripheral nervous system neoplasm	2.82e-05	9.14e-05	CcSEcCtD
Bortezomib—Cough—Doxorubicin—peripheral nervous system neoplasm	2.81e-05	9.11e-05	CcSEcCtD
Bortezomib—Shock—Epirubicin—peripheral nervous system neoplasm	2.79e-05	9.06e-05	CcSEcCtD
Bortezomib—Convulsion—Doxorubicin—peripheral nervous system neoplasm	2.79e-05	9.04e-05	CcSEcCtD
Bortezomib—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	2.78e-05	9.03e-05	CcSEcCtD
Bortezomib—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	2.78e-05	9.01e-05	CcSEcCtD
Bortezomib—Hypertension—Doxorubicin—peripheral nervous system neoplasm	2.78e-05	9.01e-05	CcSEcCtD
Bortezomib—Tachycardia—Epirubicin—peripheral nervous system neoplasm	2.77e-05	8.98e-05	CcSEcCtD
Bortezomib—Skin disorder—Epirubicin—peripheral nervous system neoplasm	2.76e-05	8.94e-05	CcSEcCtD
Bortezomib—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	2.74e-05	8.9e-05	CcSEcCtD
Bortezomib—Chest pain—Doxorubicin—peripheral nervous system neoplasm	2.74e-05	8.88e-05	CcSEcCtD
Bortezomib—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	2.74e-05	8.88e-05	CcSEcCtD
Bortezomib—Myalgia—Doxorubicin—peripheral nervous system neoplasm	2.74e-05	8.88e-05	CcSEcCtD
Bortezomib—Anxiety—Doxorubicin—peripheral nervous system neoplasm	2.73e-05	8.85e-05	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	2.72e-05	8.82e-05	CcSEcCtD
Bortezomib—Discomfort—Doxorubicin—peripheral nervous system neoplasm	2.71e-05	8.78e-05	CcSEcCtD
Bortezomib—Anorexia—Epirubicin—peripheral nervous system neoplasm	2.7e-05	8.77e-05	CcSEcCtD
Bortezomib—Hypotension—Epirubicin—peripheral nervous system neoplasm	2.65e-05	8.6e-05	CcSEcCtD
Bortezomib—Confusional state—Doxorubicin—peripheral nervous system neoplasm	2.65e-05	8.59e-05	CcSEcCtD
Bortezomib—Anaphylactic shock—Doxorubicin—peripheral nervous system neoplasm	2.62e-05	8.52e-05	CcSEcCtD
Bortezomib—Oedema—Doxorubicin—peripheral nervous system neoplasm	2.62e-05	8.52e-05	CcSEcCtD
Bortezomib—PSMB8—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	2.62e-05	0.000247	CbGpPWpGaD
Bortezomib—Infection—Doxorubicin—peripheral nervous system neoplasm	2.61e-05	8.46e-05	CcSEcCtD
Bortezomib—PSMB8—Cell Cycle—MYC—peripheral nervous system neoplasm	2.61e-05	0.000246	CbGpPWpGaD
Bortezomib—PSMB5—Adaptive Immune System—NRAS—peripheral nervous system neoplasm	2.6e-05	0.000245	CbGpPWpGaD
Bortezomib—PSMB1—Adaptive Immune System—NRAS—peripheral nervous system neoplasm	2.6e-05	0.000245	CbGpPWpGaD
Bortezomib—PSMB2—Adaptive Immune System—NRAS—peripheral nervous system neoplasm	2.6e-05	0.000245	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—PTPN11—peripheral nervous system neoplasm	2.59e-05	0.000244	CbGpPWpGaD
Bortezomib—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	2.58e-05	8.39e-05	CcSEcCtD
Bortezomib—Shock—Doxorubicin—peripheral nervous system neoplasm	2.58e-05	8.38e-05	CcSEcCtD
Bortezomib—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	2.57e-05	8.35e-05	CcSEcCtD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	2.57e-05	0.000243	CbGpPWpGaD
Bortezomib—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	2.57e-05	8.34e-05	CcSEcCtD
Bortezomib—Insomnia—Epirubicin—peripheral nervous system neoplasm	2.57e-05	8.33e-05	CcSEcCtD
Bortezomib—PSMB8—Adaptive Immune System—NRAS—peripheral nervous system neoplasm	2.56e-05	0.000242	CbGpPWpGaD
Bortezomib—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	2.56e-05	8.31e-05	CcSEcCtD
Bortezomib—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	2.55e-05	8.27e-05	CcSEcCtD
Bortezomib—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	2.55e-05	8.27e-05	CcSEcCtD
Bortezomib—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	2.54e-05	8.23e-05	CcSEcCtD
Bortezomib—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	2.53e-05	8.21e-05	CcSEcCtD
Bortezomib—PSMA1—Disease—ERBB2—peripheral nervous system neoplasm	2.53e-05	0.000238	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—COX2—peripheral nervous system neoplasm	2.52e-05	0.000238	CbGpPWpGaD
Bortezomib—PSMD1—Disease—ERBB2—peripheral nervous system neoplasm	2.51e-05	0.000237	CbGpPWpGaD
Bortezomib—PSMA1—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	2.51e-05	0.000237	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—GNS—peripheral nervous system neoplasm	2.51e-05	0.000237	CbGpPWpGaD
Bortezomib—Anorexia—Doxorubicin—peripheral nervous system neoplasm	2.5e-05	8.12e-05	CcSEcCtD
Bortezomib—PSMD2—Disease—ERBB2—peripheral nervous system neoplasm	2.5e-05	0.000236	CbGpPWpGaD
Bortezomib—PSMD1—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	2.5e-05	0.000236	CbGpPWpGaD
Bortezomib—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	2.5e-05	8.1e-05	CcSEcCtD
Bortezomib—PSMD2—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	2.49e-05	0.000234	CbGpPWpGaD
Bortezomib—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	2.47e-05	8e-05	CcSEcCtD
Bortezomib—Hypotension—Doxorubicin—peripheral nervous system neoplasm	2.45e-05	7.96e-05	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	2.45e-05	7.95e-05	CcSEcCtD
Bortezomib—Fatigue—Epirubicin—peripheral nervous system neoplasm	2.45e-05	7.94e-05	CcSEcCtD
Bortezomib—PSMB5—Signaling Pathways—GNAS—peripheral nervous system neoplasm	2.44e-05	0.00023	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—GNAS—peripheral nervous system neoplasm	2.44e-05	0.00023	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—GNAS—peripheral nervous system neoplasm	2.44e-05	0.00023	CbGpPWpGaD
Bortezomib—Pain—Epirubicin—peripheral nervous system neoplasm	2.43e-05	7.87e-05	CcSEcCtD
Bortezomib—Constipation—Epirubicin—peripheral nervous system neoplasm	2.43e-05	7.87e-05	CcSEcCtD
Bortezomib—PSMB5—Disease—PTPN11—peripheral nervous system neoplasm	2.42e-05	0.000228	CbGpPWpGaD
Bortezomib—PSMB1—Disease—PTPN11—peripheral nervous system neoplasm	2.42e-05	0.000228	CbGpPWpGaD
Bortezomib—PSMB2—Disease—PTPN11—peripheral nervous system neoplasm	2.42e-05	0.000228	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—HSD17B12—peripheral nervous system neoplasm	2.41e-05	0.000228	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—GNAS—peripheral nervous system neoplasm	2.41e-05	0.000227	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—NME1—peripheral nervous system neoplasm	2.4e-05	0.000227	CbGpPWpGaD
Bortezomib—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	2.39e-05	7.76e-05	CcSEcCtD
Bortezomib—PSMB8—Disease—PTPN11—peripheral nervous system neoplasm	2.39e-05	0.000225	CbGpPWpGaD
Bortezomib—Insomnia—Doxorubicin—peripheral nervous system neoplasm	2.37e-05	7.7e-05	CcSEcCtD
Bortezomib—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	2.36e-05	7.65e-05	CcSEcCtD
Bortezomib—PTGS1—Metabolism—ENO2—peripheral nervous system neoplasm	2.35e-05	0.000222	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	2.35e-05	0.000221	CbGpPWpGaD
Bortezomib—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	2.34e-05	7.59e-05	CcSEcCtD
Bortezomib—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	2.34e-05	7.59e-05	CcSEcCtD
Bortezomib—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	2.32e-05	7.53e-05	CcSEcCtD
Bortezomib—CYP2C8—Metabolism—COX2—peripheral nervous system neoplasm	2.31e-05	0.000218	CbGpPWpGaD
Bortezomib—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	2.31e-05	7.5e-05	CcSEcCtD
Bortezomib—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	2.28e-05	7.4e-05	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	2.27e-05	7.35e-05	CcSEcCtD
Bortezomib—Fatigue—Doxorubicin—peripheral nervous system neoplasm	2.26e-05	7.34e-05	CcSEcCtD
Bortezomib—Urticaria—Epirubicin—peripheral nervous system neoplasm	2.25e-05	7.31e-05	CcSEcCtD
Bortezomib—Pain—Doxorubicin—peripheral nervous system neoplasm	2.24e-05	7.28e-05	CcSEcCtD
Bortezomib—Constipation—Doxorubicin—peripheral nervous system neoplasm	2.24e-05	7.28e-05	CcSEcCtD
Bortezomib—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	2.24e-05	7.28e-05	CcSEcCtD
Bortezomib—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	2.24e-05	7.28e-05	CcSEcCtD
Bortezomib—CYP2C19—Metabolism—GNS—peripheral nervous system neoplasm	2.24e-05	0.000211	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	2.24e-05	0.000211	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	2.23e-05	0.00021	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	2.22e-05	0.000209	CbGpPWpGaD
Bortezomib—PSMA1—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	2.22e-05	0.000209	CbGpPWpGaD
Bortezomib—PSMD1—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	2.21e-05	0.000208	CbGpPWpGaD
Bortezomib—PSMD2—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	2.2e-05	0.000207	CbGpPWpGaD
Bortezomib—PSMB5—Cell Cycle—TP53—peripheral nervous system neoplasm	2.17e-05	0.000205	CbGpPWpGaD
Bortezomib—PSMB1—Cell Cycle—TP53—peripheral nervous system neoplasm	2.17e-05	0.000205	CbGpPWpGaD
Bortezomib—PSMB2—Cell Cycle—TP53—peripheral nervous system neoplasm	2.17e-05	0.000205	CbGpPWpGaD
Bortezomib—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	2.16e-05	7.02e-05	CcSEcCtD
Bortezomib—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	2.15e-05	6.96e-05	CcSEcCtD
Bortezomib—CYP2C19—Metabolism—NME1—peripheral nervous system neoplasm	2.15e-05	0.000202	CbGpPWpGaD
Bortezomib—PSMB8—Cell Cycle—TP53—peripheral nervous system neoplasm	2.14e-05	0.000202	CbGpPWpGaD
Bortezomib—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	2.09e-05	6.78e-05	CcSEcCtD
Bortezomib—Urticaria—Doxorubicin—peripheral nervous system neoplasm	2.09e-05	6.77e-05	CcSEcCtD
Bortezomib—PSMA1—Immune System—NRAS—peripheral nervous system neoplasm	2.08e-05	0.000196	CbGpPWpGaD
Bortezomib—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	2.07e-05	6.73e-05	CcSEcCtD
Bortezomib—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	2.07e-05	6.73e-05	CcSEcCtD
Bortezomib—PSMB5—Immune System—ERBB2—peripheral nervous system neoplasm	2.07e-05	0.000196	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—ERBB2—peripheral nervous system neoplasm	2.07e-05	0.000196	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—ERBB2—peripheral nervous system neoplasm	2.07e-05	0.000196	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—NRAS—peripheral nervous system neoplasm	2.07e-05	0.000195	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—COX2—peripheral nervous system neoplasm	2.07e-05	0.000195	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—NRAS—peripheral nervous system neoplasm	2.06e-05	0.000194	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GNS—peripheral nervous system neoplasm	2.06e-05	0.000194	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—ERBB2—peripheral nervous system neoplasm	2.04e-05	0.000193	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GNS—peripheral nervous system neoplasm	2.04e-05	0.000193	CbGpPWpGaD
Bortezomib—Asthenia—Epirubicin—peripheral nervous system neoplasm	2.04e-05	6.6e-05	CcSEcCtD
Bortezomib—Pruritus—Epirubicin—peripheral nervous system neoplasm	2.01e-05	6.51e-05	CcSEcCtD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	2.01e-05	0.000189	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—BCHE—peripheral nervous system neoplasm	1.99e-05	0.000187	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—NME1—peripheral nervous system neoplasm	1.97e-05	0.000186	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—NME1—peripheral nervous system neoplasm	1.96e-05	0.000185	CbGpPWpGaD
Bortezomib—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	1.94e-05	6.3e-05	CcSEcCtD
Bortezomib—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	1.93e-05	6.28e-05	CcSEcCtD
Bortezomib—PSMA1—Gene Expression—MYC—peripheral nervous system neoplasm	1.93e-05	0.000182	CbGpPWpGaD
Bortezomib—PSMA1—Disease—NRAS—peripheral nervous system neoplasm	1.92e-05	0.000181	CbGpPWpGaD
Bortezomib—PSMD1—Gene Expression—MYC—peripheral nervous system neoplasm	1.92e-05	0.000181	CbGpPWpGaD
Bortezomib—PSMB5—Disease—ERBB2—peripheral nervous system neoplasm	1.91e-05	0.000181	CbGpPWpGaD
Bortezomib—PSMB2—Disease—ERBB2—peripheral nervous system neoplasm	1.91e-05	0.000181	CbGpPWpGaD
Bortezomib—PSMB1—Disease—ERBB2—peripheral nervous system neoplasm	1.91e-05	0.000181	CbGpPWpGaD
Bortezomib—PSMD1—Disease—NRAS—peripheral nervous system neoplasm	1.91e-05	0.00018	CbGpPWpGaD
Bortezomib—PSMD2—Gene Expression—MYC—peripheral nervous system neoplasm	1.91e-05	0.00018	CbGpPWpGaD
Bortezomib—PSMD2—Disease—NRAS—peripheral nervous system neoplasm	1.9e-05	0.000179	CbGpPWpGaD
Bortezomib—PSMB5—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	1.9e-05	0.000179	CbGpPWpGaD
Bortezomib—PSMB2—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	1.9e-05	0.000179	CbGpPWpGaD
Bortezomib—PSMB1—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	1.9e-05	0.000179	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—COX2—peripheral nervous system neoplasm	1.9e-05	0.000179	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.9e-05	0.000179	CbGpPWpGaD
Bortezomib—PSMB8—Disease—ERBB2—peripheral nervous system neoplasm	1.89e-05	0.000178	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—COX2—peripheral nervous system neoplasm	1.88e-05	0.000178	CbGpPWpGaD
Bortezomib—Asthenia—Doxorubicin—peripheral nervous system neoplasm	1.88e-05	6.11e-05	CcSEcCtD
Bortezomib—Dizziness—Epirubicin—peripheral nervous system neoplasm	1.88e-05	6.09e-05	CcSEcCtD
Bortezomib—PSMB8—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	1.88e-05	0.000177	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—TH—peripheral nervous system neoplasm	1.87e-05	0.000176	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—HSD17B12—peripheral nervous system neoplasm	1.86e-05	0.000176	CbGpPWpGaD
Bortezomib—Pruritus—Doxorubicin—peripheral nervous system neoplasm	1.86e-05	6.03e-05	CcSEcCtD
Bortezomib—Vomiting—Epirubicin—peripheral nervous system neoplasm	1.8e-05	5.85e-05	CcSEcCtD
Bortezomib—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	1.8e-05	5.83e-05	CcSEcCtD
Bortezomib—PSMA1—Disease—MYC—peripheral nervous system neoplasm	1.79e-05	0.000169	CbGpPWpGaD
Bortezomib—Rash—Epirubicin—peripheral nervous system neoplasm	1.79e-05	5.8e-05	CcSEcCtD
Bortezomib—Dermatitis—Epirubicin—peripheral nervous system neoplasm	1.79e-05	5.8e-05	CcSEcCtD
Bortezomib—PSMD1—Disease—MYC—peripheral nervous system neoplasm	1.78e-05	0.000168	CbGpPWpGaD
Bortezomib—Headache—Epirubicin—peripheral nervous system neoplasm	1.78e-05	5.77e-05	CcSEcCtD
Bortezomib—PSMD2—Disease—MYC—peripheral nervous system neoplasm	1.77e-05	0.000167	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.77e-05	0.000167	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.76e-05	0.000166	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.75e-05	0.000165	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GNS—peripheral nervous system neoplasm	1.74e-05	0.000165	CbGpPWpGaD
Bortezomib—Dizziness—Doxorubicin—peripheral nervous system neoplasm	1.74e-05	5.63e-05	CcSEcCtD
Bortezomib—PSMB1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.7e-05	0.00016	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.7e-05	0.00016	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.7e-05	0.00016	CbGpPWpGaD
Bortezomib—Nausea—Epirubicin—peripheral nervous system neoplasm	1.68e-05	5.47e-05	CcSEcCtD
Bortezomib—PSMB2—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	1.68e-05	0.000158	CbGpPWpGaD
Bortezomib—PSMB5—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	1.68e-05	0.000158	CbGpPWpGaD
Bortezomib—PSMB1—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	1.68e-05	0.000158	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—NME1—peripheral nervous system neoplasm	1.67e-05	0.000158	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.67e-05	0.000158	CbGpPWpGaD
Bortezomib—Vomiting—Doxorubicin—peripheral nervous system neoplasm	1.67e-05	5.42e-05	CcSEcCtD
Bortezomib—CYP1A1—Metabolism—ENO2—peripheral nervous system neoplasm	1.66e-05	0.000156	CbGpPWpGaD
Bortezomib—PSMB8—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	1.66e-05	0.000156	CbGpPWpGaD
Bortezomib—Rash—Doxorubicin—peripheral nervous system neoplasm	1.65e-05	5.37e-05	CcSEcCtD
Bortezomib—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	1.65e-05	5.37e-05	CcSEcCtD
Bortezomib—Headache—Doxorubicin—peripheral nervous system neoplasm	1.64e-05	5.34e-05	CcSEcCtD
Bortezomib—CYP1A2—Metabolism—COX2—peripheral nervous system neoplasm	1.61e-05	0.000152	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.61e-05	0.000151	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.6e-05	0.000151	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.59e-05	0.00015	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—NRAS—peripheral nervous system neoplasm	1.58e-05	0.000149	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—NRAS—peripheral nervous system neoplasm	1.58e-05	0.000149	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—NRAS—peripheral nervous system neoplasm	1.58e-05	0.000149	CbGpPWpGaD
Bortezomib—Nausea—Doxorubicin—peripheral nervous system neoplasm	1.56e-05	5.06e-05	CcSEcCtD
Bortezomib—PSMB8—Immune System—NRAS—peripheral nervous system neoplasm	1.55e-05	0.000147	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—GNAS—peripheral nervous system neoplasm	1.53e-05	0.000144	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—HRAS—peripheral nervous system neoplasm	1.52e-05	0.000144	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—ENO2—peripheral nervous system neoplasm	1.52e-05	0.000143	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—HRAS—peripheral nervous system neoplasm	1.52e-05	0.000143	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—HRAS—peripheral nervous system neoplasm	1.51e-05	0.000142	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—ABCB1—peripheral nervous system neoplasm	1.5e-05	0.000141	CbGpPWpGaD
Bortezomib—PSMB1—Gene Expression—MYC—peripheral nervous system neoplasm	1.46e-05	0.000138	CbGpPWpGaD
Bortezomib—PSMB5—Gene Expression—MYC—peripheral nervous system neoplasm	1.46e-05	0.000138	CbGpPWpGaD
Bortezomib—PSMB2—Gene Expression—MYC—peripheral nervous system neoplasm	1.46e-05	0.000138	CbGpPWpGaD
Bortezomib—PSMB2—Disease—NRAS—peripheral nervous system neoplasm	1.46e-05	0.000137	CbGpPWpGaD
Bortezomib—PSMB5—Disease—NRAS—peripheral nervous system neoplasm	1.46e-05	0.000137	CbGpPWpGaD
Bortezomib—PSMB1—Disease—NRAS—peripheral nervous system neoplasm	1.46e-05	0.000137	CbGpPWpGaD
Bortezomib—PSMB8—Gene Expression—MYC—peripheral nervous system neoplasm	1.44e-05	0.000136	CbGpPWpGaD
Bortezomib—PSMB8—Disease—NRAS—peripheral nervous system neoplasm	1.44e-05	0.000135	CbGpPWpGaD
Bortezomib—PSMA1—Disease—HRAS—peripheral nervous system neoplasm	1.41e-05	0.000133	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—BCHE—peripheral nervous system neoplasm	1.4e-05	0.000132	CbGpPWpGaD
Bortezomib—PSMD1—Disease—HRAS—peripheral nervous system neoplasm	1.4e-05	0.000132	CbGpPWpGaD
Bortezomib—PSMD2—Disease—HRAS—peripheral nervous system neoplasm	1.39e-05	0.000131	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—ENO2—peripheral nervous system neoplasm	1.36e-05	0.000128	CbGpPWpGaD
Bortezomib—PSMB5—Disease—MYC—peripheral nervous system neoplasm	1.36e-05	0.000128	CbGpPWpGaD
Bortezomib—PSMB2—Disease—MYC—peripheral nervous system neoplasm	1.36e-05	0.000128	CbGpPWpGaD
Bortezomib—PSMB1—Disease—MYC—peripheral nervous system neoplasm	1.36e-05	0.000128	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GNS—peripheral nervous system neoplasm	1.35e-05	0.000127	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.35e-05	0.000127	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—AKT1—peripheral nervous system neoplasm	1.34e-05	0.000127	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.34e-05	0.000126	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.34e-05	0.000126	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.34e-05	0.000126	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.34e-05	0.000126	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—AKT1—peripheral nervous system neoplasm	1.34e-05	0.000126	CbGpPWpGaD
Bortezomib—PSMB8—Disease—MYC—peripheral nervous system neoplasm	1.34e-05	0.000126	CbGpPWpGaD
Bortezomib—PSMA1—Gene Expression—AKT1—peripheral nervous system neoplasm	1.34e-05	0.000126	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.34e-05	0.000126	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.33e-05	0.000126	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—AKT1—peripheral nervous system neoplasm	1.33e-05	0.000126	CbGpPWpGaD
Bortezomib—PSMD1—Gene Expression—AKT1—peripheral nervous system neoplasm	1.33e-05	0.000125	CbGpPWpGaD
Bortezomib—PSMD2—Gene Expression—AKT1—peripheral nervous system neoplasm	1.32e-05	0.000125	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.32e-05	0.000125	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—TH—peripheral nervous system neoplasm	1.32e-05	0.000124	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—NME1—peripheral nervous system neoplasm	1.29e-05	0.000122	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—BCHE—peripheral nervous system neoplasm	1.28e-05	0.000121	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.25e-05	0.000118	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ENO2—peripheral nervous system neoplasm	1.25e-05	0.000118	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.25e-05	0.000118	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—COX2—peripheral nervous system neoplasm	1.24e-05	0.000117	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.24e-05	0.000117	CbGpPWpGaD
Bortezomib—PSMA1—Disease—AKT1—peripheral nervous system neoplasm	1.24e-05	0.000117	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ENO2—peripheral nervous system neoplasm	1.24e-05	0.000117	CbGpPWpGaD
Bortezomib—PSMD1—Disease—AKT1—peripheral nervous system neoplasm	1.24e-05	0.000116	CbGpPWpGaD
Bortezomib—PSMD2—Disease—AKT1—peripheral nervous system neoplasm	1.23e-05	0.000116	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.22e-05	0.000116	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.22e-05	0.000115	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.22e-05	0.000115	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.22e-05	0.000115	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—TH—peripheral nervous system neoplasm	1.21e-05	0.000114	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.2e-05	0.000113	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—HRAS—peripheral nervous system neoplasm	1.15e-05	0.000109	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—HRAS—peripheral nervous system neoplasm	1.15e-05	0.000109	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—HRAS—peripheral nervous system neoplasm	1.15e-05	0.000109	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—BCHE—peripheral nervous system neoplasm	1.15e-05	0.000108	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—HRAS—peripheral nervous system neoplasm	1.14e-05	0.000107	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.09e-05	0.000103	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—TH—peripheral nervous system neoplasm	1.08e-05	0.000102	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—GNAS—peripheral nervous system neoplasm	1.07e-05	0.000101	CbGpPWpGaD
Bortezomib—PSMB5—Disease—HRAS—peripheral nervous system neoplasm	1.07e-05	0.0001	CbGpPWpGaD
Bortezomib—PSMB2—Disease—HRAS—peripheral nervous system neoplasm	1.07e-05	0.0001	CbGpPWpGaD
Bortezomib—PSMB1—Disease—HRAS—peripheral nervous system neoplasm	1.07e-05	0.0001	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ENO2—peripheral nervous system neoplasm	1.06e-05	9.97e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—ABCB1—peripheral nervous system neoplasm	1.05e-05	9.95e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—BCHE—peripheral nervous system neoplasm	1.05e-05	9.94e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—HRAS—peripheral nervous system neoplasm	1.05e-05	9.91e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—BCHE—peripheral nervous system neoplasm	1.04e-05	9.86e-05	CbGpPWpGaD
Bortezomib—PSMA1—Metabolism—AKT1—peripheral nervous system neoplasm	1.04e-05	9.8e-05	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—AKT1—peripheral nervous system neoplasm	1.03e-05	9.76e-05	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—AKT1—peripheral nervous system neoplasm	1.03e-05	9.71e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.03e-05	9.71e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.02e-05	9.66e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.02e-05	9.62e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.02e-05	9.62e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.02e-05	9.62e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.02e-05	9.62e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—AKT1—peripheral nervous system neoplasm	1.02e-05	9.61e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—AKT1—peripheral nervous system neoplasm	1.02e-05	9.61e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—AKT1—peripheral nervous system neoplasm	1.02e-05	9.61e-05	CbGpPWpGaD
Bortezomib—PSMB1—Gene Expression—AKT1—peripheral nervous system neoplasm	1.01e-05	9.55e-05	CbGpPWpGaD
Bortezomib—PSMB5—Gene Expression—AKT1—peripheral nervous system neoplasm	1.01e-05	9.55e-05	CbGpPWpGaD
Bortezomib—PSMB2—Gene Expression—AKT1—peripheral nervous system neoplasm	1.01e-05	9.55e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.01e-05	9.48e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.01e-05	9.48e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—AKT1—peripheral nervous system neoplasm	1e-05	9.47e-05	CbGpPWpGaD
Bortezomib—PSMB8—Gene Expression—AKT1—peripheral nervous system neoplasm	9.99e-06	9.42e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—SLC2A1—peripheral nervous system neoplasm	9.97e-06	9.4e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—TH—peripheral nervous system neoplasm	9.91e-06	9.35e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—GNAS—peripheral nervous system neoplasm	9.85e-06	9.29e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	9.84e-06	9.28e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—TH—peripheral nervous system neoplasm	9.82e-06	9.27e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	9.8e-06	9.24e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—HRAS—peripheral nervous system neoplasm	9.75e-06	9.2e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—ABCB1—peripheral nervous system neoplasm	9.67e-06	9.12e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—MYC—peripheral nervous system neoplasm	9.5e-06	8.96e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—MYC—peripheral nervous system neoplasm	9.5e-06	8.96e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—MYC—peripheral nervous system neoplasm	9.5e-06	8.96e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—AKT1—peripheral nervous system neoplasm	9.41e-06	8.87e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—AKT1—peripheral nervous system neoplasm	9.41e-06	8.87e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—AKT1—peripheral nervous system neoplasm	9.41e-06	8.87e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—MYC—peripheral nervous system neoplasm	9.36e-06	8.83e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—AKT1—peripheral nervous system neoplasm	9.27e-06	8.75e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—BCHE—peripheral nervous system neoplasm	8.93e-06	8.42e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—GNAS—peripheral nervous system neoplasm	8.8e-06	8.3e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	8.69e-06	8.2e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	8.65e-06	8.16e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—ABCB1—peripheral nervous system neoplasm	8.63e-06	8.14e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—AKT1—peripheral nervous system neoplasm	8.61e-06	8.12e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—SLC2A1—peripheral nervous system neoplasm	8.52e-06	8.03e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—TH—peripheral nervous system neoplasm	8.4e-06	7.92e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ENO2—peripheral nervous system neoplasm	8.16e-06	7.69e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GNAS—peripheral nervous system neoplasm	8.09e-06	7.63e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GNAS—peripheral nervous system neoplasm	8.02e-06	7.56e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ABCB1—peripheral nervous system neoplasm	7.94e-06	7.49e-05	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—AKT1—peripheral nervous system neoplasm	7.88e-06	7.43e-05	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—AKT1—peripheral nervous system neoplasm	7.88e-06	7.43e-05	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—AKT1—peripheral nervous system neoplasm	7.88e-06	7.43e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ABCB1—peripheral nervous system neoplasm	7.87e-06	7.42e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—TP53—peripheral nervous system neoplasm	7.8e-06	7.36e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—TP53—peripheral nervous system neoplasm	7.8e-06	7.36e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—TP53—peripheral nervous system neoplasm	7.8e-06	7.36e-05	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—AKT1—peripheral nervous system neoplasm	7.77e-06	7.32e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—TP53—peripheral nervous system neoplasm	7.69e-06	7.25e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	7.46e-06	7.04e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—HRAS—peripheral nervous system neoplasm	7.46e-06	7.04e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—HRAS—peripheral nervous system neoplasm	7.46e-06	7.04e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—HRAS—peripheral nervous system neoplasm	7.35e-06	6.94e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—BCHE—peripheral nervous system neoplasm	6.89e-06	6.5e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GNAS—peripheral nervous system neoplasm	6.85e-06	6.46e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ABCB1—peripheral nervous system neoplasm	6.73e-06	6.34e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—AKT1—peripheral nervous system neoplasm	6.59e-06	6.21e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—AKT1—peripheral nervous system neoplasm	6.59e-06	6.21e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	6.59e-06	6.21e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—SLC2A1—peripheral nervous system neoplasm	6.57e-06	6.2e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—AKT1—peripheral nervous system neoplasm	6.49e-06	6.12e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—TH—peripheral nervous system neoplasm	6.48e-06	6.11e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GNAS—peripheral nervous system neoplasm	5.29e-06	4.99e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ABCB1—peripheral nervous system neoplasm	5.19e-06	4.9e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—AKT1—peripheral nervous system neoplasm	4.12e-06	3.88e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—AKT1—peripheral nervous system neoplasm	2.9e-06	2.74e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—AKT1—peripheral nervous system neoplasm	2.66e-06	2.51e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—AKT1—peripheral nervous system neoplasm	2.37e-06	2.24e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—AKT1—peripheral nervous system neoplasm	2.18e-06	2.06e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—AKT1—peripheral nervous system neoplasm	2.16e-06	2.04e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—AKT1—peripheral nervous system neoplasm	1.85e-06	1.74e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—AKT1—peripheral nervous system neoplasm	1.43e-06	1.35e-05	CbGpPWpGaD
